KPV

KPV (Lysine-Proline-Valine) is a tripeptide fragment of the endogenous neuropeptide α-MSH, representing its biologically active C-terminal tripeptide sequence (positions 11–13). The parent peptide α-MSH is produced by the pituitary gland and exerts broad anti-inflammatory and immunomodulatory effects through MC1R binding.

Critically, KPV retains the full anti-inflammatory potency of α-MSH without binding to melanocortin receptors, meaning it produces no pigmentation, hormonal, or systemic side effects. It penetrates gut epithelium and inflamed tissue directly, making it a leading candidate for localized inflammatory bowel conditions. Oral delivery in nanoparticle carriers has shown particular promise in murine colitis models.

// NF-κB PATHWAY SUPPRESSION

KPV directly inhibits the nuclear translocation of NF-κB p65, the master regulator of pro-inflammatory cytokine production. This blocks downstream expression of TNF-α, IL-1β, IL-6, and IL-8 in macrophages and intestinal epithelial cells.

// EPITHELIAL BARRIER RESTORATION

Beyond cytokine suppression, KPV promotes tight junction protein expression (occludin, claudin-1), restoring gut barrier integrity that is compromised in IBD. It also reduces mast cell degranulation in inflamed mucosa.